Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 8/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.31 |
| ▸ | FEN1 | P39748 | 3/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | GAK | O14976 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16764935 | 0.81 | ATR (0.32) | ATR | |
| SCHEMBL30309956 | 0.81 | ATR (0.40) | ATR | |
| SCHEMBL15778418 | 0.81 | ATR (0.40) | ATR | |
| SCHEMBL15783954 | 0.81 | TGFBR1 (0.36) | ATRKDM4ETGFBR1ACVR1GAK | |
| SCHEMBL15770455 | 0.80 | ATR (0.43) | ATRKDM4E | |
| SCHEMBL15786982 | 0.80 | ATR (0.41) | ATRKDM4E | |
| SCHEMBL29932156 | 0.80 | ATR (0.41) | ATRKDM4E | |
| SCHEMBL22477057 | 0.74 | KMT2A (0.42) | ATRKDM4E | |
| SCHEMBL15778799 | 0.74 | ATR (0.52) | ATR | |
| SCHEMBL19951457 | 0.73 | NEK2 (0.47) | ATRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| EP-4534538-A2 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-4190786-B1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMA (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| EP-4190786-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Incorporated (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3808749-B1 | PYRAZOLO[1,5-A]PYRIMIDINES USEFUL AS INHIBITORS OF ATR KINASE FOR THE TREATMENT OF CANCER DISEASES | VERTEX PHARMA (US) | 2023-03-08 | — | — | EP | disclosed |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-06-28 | — | — | US | disclosed |
| US-20160347754-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-01 | — | — | US | disclosed |
| US-9340546-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2941432-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | Vertex Pharmaceuticals Inc. (US) | 2015-11-11 | — | — | EP | disclosed |
| WO-2014089379-A9 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2014089379-A9 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140249157-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-04 | — | — | US | disclosed |
| US-20140249157-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-09-04 | — | — | US | disclosed |
| US-20140163000-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2014-06-12 | — | — | US | disclosed |
| WO-2014089379-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | WO | disclosed |
| WO-2014089379-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249157-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | ATR 1/4885FAAH 4718/4885KDM4E 2263/4885 |
| US-20140163000-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | ATR 1/4885FAAH 4718/4885KDM4E 2263/4885 |
| US-20160347754-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | ATR 1/4885FAAH 4740/4885KDM4E 2266/4885 |
| US-20250223292-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, CHEK1 | ATR 1/4885FAAH 4718/4885KDM4E 2263/4885 |
| US-20230271963-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | ATR 1/4885FAAH 4740/4885KDM4E 2266/4885 |
| US-12187731-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, CHEK1 | ATR 1/4885FAAH 4718/4885KDM4E 2263/4885 |
| US-11370798-B2 | Compounds useful as inhibitors of ATR kinase | ATR, MAP3K20, TBK1 | ATR 1/4885FAAH 4740/4885KDM4E 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.